Peanut oral immunotherapy in adolescents: study protocol for a randomized controlled trial

Area of Science:

• Allergy and Immunology
• Pediatric Gastroenterology
• Clinical Trials

Background:

• Peanut allergy is a prevalent and growing health concern.
• Current management relies on strict allergen avoidance.
• Oral immunotherapy (OIT) offers a potential therapeutic strategy, with emerging positive outcomes in children.

Purpose of the Study:

• To assess the efficacy and safety of peanut OIT in individuals aged 12-18 years with confirmed peanut allergy.
• To determine if OIT can increase tolerance to peanut, thereby reducing the risk of severe reactions.
• To improve the quality of life for adolescent peanut allergy patients.

Main Methods:

• A randomized, double-blind, placebo-controlled, multicenter trial involving 12- to 18-year-olds.
• Gradual up-dosing of peanut or placebo from 10 mg to 2 g over 24 weeks.
• A subsequent unblinded maintenance phase and ongoing monitoring of adverse events.

Main Results:

• The primary endpoint is the proportion of patients achieving tolerance (negative double-blind, placebo-controlled food challenge at 2g peanut) post-build-up.
• Secondary endpoints include sustained desensitization, adverse event rates, and immunological markers.
• Immunological assays will track changes throughout the study.

Conclusions:

• This study represents a novel evaluation of OIT specifically in the adolescent population.
• It aims to provide evidence for reducing severe reactions from accidental peanut exposure.
• The findings could significantly impact treatment guidelines and patient quality of life.